Follow-up

Following up on my Dermatology Risk-Reward post, safety and efficacy dimensions could be expanded to include a cost (to patients) dimension, as I diagrammed below. Green represents PH-10, and the orange cylinders are illustrative of competing compounds with different dimensional features: e.g., comparable efficacy but lower safety and higher cost, higher efficacy but lower safety and higher cost, etc. PH-10 has a very low manufacturing cost, which provides Provectus/the eventual derm pharma licensee with significant (enormous) pricing flexibility to facilitate market entry and, over time, to grab market share.

PH-10 targets abnormal tissue for dermatological afflictions like atopic dermatitis and psoriasis (much like PV-10's targeting for oncology indications). There is selective epithelial uptake, and it is activated by ambient visible light within minutes. There is minimal toxicity in normal tissue, and no systemic uptake. PH-10's topical administration (it is a a topical aqueous hydrogel of rose bengal disodium) maximizes local potency, and minimizes the potential for systemic adverse effects. It photobleaches (fades) to an inactive state.